Detection of Misfolded Aβ Oligomers for Sensitive Biochemical Diagnosis of Alzheimer's Disease

Cell Reports

Volumn 7, Issue 1, 2014, Pages 261-268

  Salvadores, Natalia ^a   Shahnawaz, Mohammad ^a   Scarpini, Elio ^b   Tagliavini, Fabrizio ^c   Soto, Claudio ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; MISFOLDED AMYLOID BETA OLIGOMER; OLIGOMER; TAU PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PROTEIN AGGREGATE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; MOLECULAR DIAGNOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN FOLDING; PROTEIN MISFOLDING CYCLIC AMPLIFICATION ASSAY; PROTEIN POLYMERIZATION; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; HUMANS; MIDDLE AGED; PROTEIN AGGREGATES; PROTEIN FOLDING;

EID: 84898026266     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.02.031     Document Type: Article

References (51)

1. Atarashi R., Wilham J.M., Christensen L., Hughson A.G., Moore R.A., Johnson L.M., Onwubiko H.A., Priola S.A., Caughey B. Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat. Methods 2008, 5:211-212.
2. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
3. Braak E., Griffing K., Arai K., Bohl J., Bratzke H., Braak H. Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?. Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249(Suppl 3):14-22.
4. Buchhave P., Minthon L., Zetterberg H., Wallin A.K., Blennow K., Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 2012, 69:98-106.
5. Castilla J., Saá P., Soto C. Detection of prions in blood. Nat. Med. 2005, 11:982-985.
6. Caughey B., Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003, 26:267-298.
7. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
8. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J.Biol. Chem. 2002, 277:32046-32053.
9. El-Agnaf O.M., Mahil D.S., Patel B.P., Austen B.M. Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem. Biophys. Res. Commun. 2000, 273:1003-1007.
10. Fukumoto H., Tokuda T., Kasai T., Ishigami N., Hidaka H., Kondo M., Allsop D., Nakagawa M. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 2010, 24:2716-2726.
11. Galimberti D., Scarpini E. Progress in Alzheimer's disease. J.Neurol. 2012, 259:201-211.
12. Gao C.M., Yam A.Y., Wang X., Magdangal E., Salisbury C., Peretz D., Zuckermann R.N., Connolly M.D., Hansson O., Minthon L., et al. Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS ONE 2010, 5:e15725.
13. Georganopoulou D.G., Chang L., Nam J.M., Thaxton C.S., Mufson E.J., Klein W.L., Mirkin C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2005, 102:2273-2276.
14. Glabe C.G., Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 2006, 66(2, Suppl 1):S74-S78.
15. Gonzalez-Romero D., Barria M.A., Leon P., Morales R., Soto C. Detection of infectious prions in urine. FEBS Lett. 2008, 582:3161-3166.
16. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
17. Head E., Pop V., Sarsoza F., Kayed R., Beckett T.L., Studzinski C.M., Tomic J.L., Glabe C.G., Murphy M.P. Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J.Alzheimers Dis. 2010, 20:637-646.
18. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
19. Jarrett J.T., Lansbury P.T. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 1993, 73:1055-1058.
20. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
21. Klein W.L., Stine W.B., Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 2004, 25:569-580.
22. Klunk W.E., Mathis C.A. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr. Opin. Neurol. 2008, 21:683-687.
23. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
24. Klyubin I., Betts V., Welzel A.T., Blennow K., Zetterberg H., Wallin A., Lemere C.A., Cullen W.K., Peng Y., Wisniewski T., et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J.Neurosci. 2008, 28:4231-4237.
25. LeVine H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993, 2:404-410.
26. Luheshi L.M., Dobson C.M. Bridging the gap: from protein misfolding to protein misfolding diseases. FEBS Lett. 2009, 583:2581-2586.
27. Maddalena A., Papassotiropoulos A., Müller-Tillmanns B., Jung H.H., Hegi T., Nitsch R.M., Hock C. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch. Neurol. 2003, 60:1202-1206.
28. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
29. Morales R., Estrada L.D., Diaz-Espinoza R., Morales-Scheihing D., Jara M.C., Castilla J., Soto C. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J.Neurosci. 2010, 30:4528-4535.
30. Morales R., Duran-Aniotz C., Diaz-Espinoza R., Camacho M.V., Soto C. Protein misfolding cyclic amplification of infectious prions. Nat. Protoc. 2012, 7:1397-1409.
31. Mulder C., Verwey N.A., van der Flier W.M., Bouwman F.H., Kok A., van Elk E.J., Scheltens P., Blankenstein M.A. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem. 2010, 56:248-253.
32. Parnetti L., Chiasserini D. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease. Biomarkers Med. 2011, 5:479-484.
33. Petersen R.C., Roberts R.O., Knopman D.S., Boeve B.F., Geda Y.E., Ivnik R.J., Smith G.E., Jack C.R. Mild cognitive impairment: ten years later. Arch. Neurol. 2009, 66:1447-1455.
34. Pitschke M., Prior R., Haupt M., Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat. Med. 1998, 4:832-834.
35. Saá P., Castilla J., Soto C. Presymptomatic detection of prions in blood. Science 2006, 313:92-94.
36. Saá P., Castilla J., Soto C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J.Biol. Chem. 2006, 281:35245-35252.
37. Saborio G.P., Permanne B., Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001, 411:810-813.
38. Santos A.N., Ewers M., Minthon L., Simm A., Silber R.E., Blennow K., Prvulovic D., Hansson O., Hampel H. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J.Alzheimers Dis. 2012, 29:171-176.
39. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N Y Acad. Sci. 2000, 924:17-25.
40. Sellebjerg F., Christiansen M. Qualitative assessment of intrathecal IgG synthesis by isoelectric focusing and immunodetection: interlaboratory reproducibility and interobserver agreement. Scand. J. Clin. Lab. Invest. 1996, 56:135-143.
41. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J.Neurosci. 2007, 27:2866-2875.
42. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4:49-60.
43. Soto C., Castaño E.M., Frangione B., Inestrosa N.C. The α-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J.Biol. Chem. 1995, 270:3063-3067.
44. Soto C., Saborio G.P., Anderes L. Cyclic amplification of proteinmisfolding: application to prion-related disorders and beyond. Trends Neurosci. 2002, 25:390-394.
45. Soto C., Estrada L., Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem. Sci. 2006, 31:150-155.
46. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289:2094-2103.
47. Terry R.D. Neuropathological changes in Alzheimer disease. Prog. Brain Res. 1994, 101:383-390.
48. Urbanelli L., Magini A., Ciccarone V., Trivelli F., Polidoro M., Tancini B., Emiliani C. New perspectives for the diagnosis of Alzheimer's disease. Recent Pat. CNS Drug Discov. 2009, 4:160-181.
49. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J.Neurochem. 2007, 101:1172-1184.
50. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation invivo. Nature 2002, 416:535-539.
51. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002, 924:133-140.